Journal of Pharmaceutical Research and Integrated Medical Sciences (JPRIMS)
ISSN: 3049-1681 | Vol. 03, Issue-02, Feb-2026 | pp.-01-12

ORIGINALARTICLE https://aktpublication.com/index.php/jprims/index

Realizing the Promise of Cancer Nanotechnology: From Therapeutic Platforms to Omics-Driven Precision Oncology and Clinical Translation

Gokul Dewangan[1], Neeraj Kumar[2], Vivek Sahu[1], Gitanjali Kashyap[1], Vinay Sagar Verma[1*]

[1]Kamla Institute of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Shri Shankaracharya Technical Campus, Junwani, Bhilai, Dist.-Durg, Chhattisgarh, India. Pin-490020*2*

[2]School of Pharmacy, Shri Shankaracharya Professional University, Junwani, Bhilai, Dist.-Durg, Chhattisgarh, India. Pin-490020

***Corresponding Email: vinaysagarverma@gmail.com**

Abstract:

Background: Cancer remains one of the leading causes of morbidity and mortality worldwide, with conventional treatment strategies limited by systemic toxicity, therapeutic resistance, and tumor heterogeneity. The emergence of nanotechnology offers innovative solutions to these challenges, enabling targeted drug delivery, controlled release, and theranostic integration. **Objective:** This review synthesizes recent progress in cancer nanomedicine, highlighting therapeutic platforms, omics-driven personalization, and clinical translation between 2019 and 2024.**Methos:** We discuss the major classes of therapeutic nanoplatforms including lipid-based systems, polymeric nanocarriers, inorganic nanoparticles, and hybrid or bioinspired designs detailing their mechanisms of action in targeted delivery, photothermal therapy, and multimodal treatment. Advances in genomics, transcriptomics, proteomics, and metabolomics are explored for their role in guiding nanocarrier design, with emphasis on artificial intelligence–enabled multi-omics integration for precision oncology. Clinical trial progress across liver, lung, pancreatic, breast, and brain cancers demonstrates improved tolerability, patient quality of life, and incremental survival gains, though translation remains constrained by tumor heterogeneity, blood–brain barrier penetration, scalability, cost, and regulatory hurdles. **Conclusion:** Cancer nanomedicine stands at a pivotal juncture advancing beyond incremental improvements to become a cornerstone of precision oncology. By uniting nanoscale engineering, multi-omics, artificial intelligence, and innovative clinical strategies, the field holds the potential to transform cancer therapy in the decade ahead.

Keywords:

Cancer Nanomedicine; Nanotechnology Therapeutic Platforms; Lipid Nanoparticles; Polymeric Nanocarriers; Cancer Therapy

Received: Oct. 23, 2025 **Revised: Nov. 30, 2025** **Accepted: Jan. 28, 2026** **Published: Feb. 19, 2026**

DOI: https://doi.org/10.64063/3049-1681.vol.3.issue2.1

https://aktpublication.com/index.php/jprims/issue/archive

1. Introduction

Cancer continues to impose an overwhelming burden on global health, accounting for millions of deaths each year and straining healthcare systems across both developed and developing nations. Despite decades of advances in surgery, chemotherapy, and radiotherapy, conventional treatments remain constrained by significant limitations including systemic toxicity, the emergence of multidrug resistance, and the biological heterogeneity of tumors that undermines long-term efficacy [1-2]. These persistent challenges have driven the search for more precise, effective, and patient-friendly therapeutic strategies.

In recent years, nanotechnology has emerged as a transformative force in oncology, bridging the gap between laboratory innovation and clinical application. Nanoscale platforms offer unique physicochemical properties that enable targeted drug delivery, controlled release, and multimodal theranostic capabilities, making them ideal candidates for overcoming the shortcomings of traditional cancer therapies. Early successes in nanoparticle-based formulations, coupled with rapidly evolving omics -driven insights into tumor biology, have positioned Nano medicine at the forefront of precision oncology [3].

This review aims to synthesize the current landscape of cancer nanotechnology, with a focus on therapeutic platforms, the integration of multi-omics for personalized treatment design, and the progress of clinical trials translating these concepts into real-world impact. By outlining both the opportunities and the roadblocks, we highlight the trajectory of nanomedicine from experimental frameworks to established clinical practices [4]. (Figure 1)



Figure 1. Conceptual roadmap of cancer nanotechnology, illustrating the transition from preclinical innovation to clinical translation, incorporating therapeutic modalities, omics integration, and trial progression.

2. Nanotechnology Therapeutic Platforms in Cancer

The therapeutic utility of nanotechnology in oncology stems from its ability to engineer carriers that overcome pharmacological limitations of conventional drugs, including poor solubility, rapid clearance, and nonspecific distribution [5]. By fine-tuning particle size, surface chemistry, and payload composition, nanoplatforms can enhance tumor selectivity, prolong circulation time, and integrate diagnostic and therapeutic modalities. Broadly, these nanosystems can be classified into lipid-based, polymeric, inorganic, and hybrid or bioinspired categories, each offering distinct functional advantages [6].Lipid-based systems such as liposomes and solid lipid nanoparticles have been among the earliest and most clinically advanced nanocarriers. Their biocompatibility, capacity for both hydrophilic and hydrophobic drug encapsulation, and surface modification potential (e.g., PEGylation, ligand conjugation) have led to FDA-approved formulations like *Doxil*® for breast and ovarian cancers. These systems excel in improving drug stability and reducing systemic toxicity, although issues with scalability and premature leakage remain challenges.Polymeric nanocarriers encompass structures such as micelles, dendrimers, and nanogels [7]. Polymeric micelles are particularly advantageous for solubilizing poorly water-soluble chemotherapeutics, while dendrimers offer precise multivalent architectures that can be conjugated with drugs, imaging agents, and targeting ligands simultaneously. Nanogels, due to their hydrophilic networks, allow high drug loading and stimulus-responsive release, making them promising for site-specific therapy. Their tunability and versatility make polymeric carriers a powerful toolkit for multifunctional delivery strategies [8].

Inorganic nanoplatforms including gold nanoparticles, mesoporous silica nanoparticles, and iron oxide nanoparticles add an additional dimension to therapy by enabling photothermal and photodynamic modalities, as well as imaging-guided treatment. Gold nanoparticles, for example, can convert near-infrared light into localized heat, selectively ablating tumors with minimal collateral damage. Similarly, iron oxide nanoparticles double as therapeutic and diagnostic (theranostic) tools due to their magnetic resonance imaging (MRI) contrast properties [9]. Despite their promise, concerns over long-term biopersistence and toxicity require careful evaluation.

Hybrid and bioinspired nanosystems are rapidly gaining momentum as next-generation cancer therapeutics. These include liposome-polymer hybrids, virus-like particles, exosomes, and cell membrane coated nanoparticles [10]. By mimicking natural biological systems, such platforms achieve enhanced biocompatibility, immune evasion, and tumor-targeting capability. For instance, red blood cell membrane coated nanoparticles prolong systemic circulation, while exosome-based carriers leverage natural intercellular communication pathways for efficient cargo delivery. Such bioinspired designs mark a paradigm shift toward highly adaptable and patient-tailored nanomedicine [11].

Mechanistically, these therapeutic nanoplatforms function through multiple pathways: passive tumor targeting via the enhanced permeability and retention (EPR) effect, active targeting through ligand-receptor interactions, controlled release triggered by pH, enzymes, or redox gradients, and energy-based interventions such as photothermal and photodynamic therapy. The convergence of these mechanisms not only enhances therapeutic efficacy but also minimizes off-target damage offering a blueprint for safer, more precise cancer care [12]. (Table1)

Table 1. Therapeutic Nano platforms and their functional attributes

Platform Type	Examples	Advantages	Mechanisms of Action	Reference
Lipid-based systems	Liposomes, Solid lipid nanoparticles	Biocompatible, encapsulate hydrophilic & hydrophobic drugs, clinically established	Passive/active targeting, controlled release	13
Polymeric nanocarriers	Micelles, Dendrimers, Nanogels	High drug loading, multifunctionalization, tunable release	Solubilization, ligand targeting, stimulus-responsive release	14
Inorganic platforms	Gold, Silica, Iron oxide nanoparticles	Imaging + therapy (theranostics), energy-based modalities	Photothermal, photodynamic, magnetic targeting	15
Hybrid & bioinspired systems	Lipid-polymer hybrids, Exosomes, Cell membrane-coated NPs	Immune evasion, biomimicry, prolonged circulation	Natural communication pathways, personalized delivery	16

3. Omics Integration in Cancer Nanomedicine

The advent of high-throughput omics technologies has revolutionized oncology, enabling a deeper understanding of tumor heterogeneity and the molecular determinants of therapy response. When coupled with nanomedicine, these insights provide a powerful framework for designing precise, patient-tailored interventions that move beyond the one-size-fits-all paradigm. Integrating genomics, transcriptomics, proteomics, and metabolomics into nanotechnology-driven cancer therapeutics represents a critical step toward true precision oncology.Genomics plays a foundational role in identifying molecular targets for nanomedicine-based therapies [17]. Whole-genome and exome sequencing allow the discovery of driver mutations, copy number variations, and genetic alterations that govern tumor initiation and progression. Nanoparticle systems can be engineered to selectively deliver small-molecule inhibitors, siRNA, or CRISPR-

Cas9 components to silence or correct oncogenic mutations [18]. For instance, lipid nanoparticles delivering siRNA against KRAS mutations have shown promise in early trials, demonstrating the feasibility of genotype-driven nanotherapy [19].

Transcriptomics and proteomics provide complementary layers of information, particularly in the context of drug resistance. RNA sequencing identifies aberrant gene expression patterns, while quantitative proteomics reveals post-translational modifications and signaling cascades that drive tumor adaptation. Incorporating these datasets allows the design of nanocarriers capable of co-delivering chemotherapeutics alongside modulators of resistance pathways, effectively sensitizing tumors to treatment. For example, polymeric micelles delivering both paclitaxel and siRNA targeting multidrug resistance genes have demonstrated synergistic efficacy in preclinical models [20].Metabolomics offers a real-time snapshot of tumor metabolic reprogramming and therapy response. By tracking shifts in metabolite concentrations, researchers can identify vulnerabilities such as altered glycolysis, glutamine dependence, or lipid metabolism. Nanoparticles can then be tailored to exploit these metabolic weaknesses either through targeted delivery of metabolic inhibitors or as sensors that provide feedback on therapeutic efficacy. Iron oxide nanoparticles conjugated with metabolic reporters, for instance, have been investigated for simultaneous monitoring of tumor metabolism and drug delivery outcomes [21].

The true potential of multi-omics integration lies in fusing these diverse datasets into a cohesive map of tumor biology. Artificial intelligence and machine learning algorithms play a pivotal role in decoding this complexity, uncovering actionable biomarkers, and predicting patient-specific responses. By linking omics-informed targets with customizable nanocarriers, researchers can design adaptive therapeutic systems where a nanoparticle's payload, release profile, and targeting ligands are guided directly by a patient's molecular profile. This convergence of multi-omics and nanomedicine paves the way for next-generation, AI-driven personalized therapies [22]. (Figure 2)



Figure 2. Omics-guided nanomedicine development pipeline: integrating genomics, transcriptomics, proteomics, and metabolomics with AI-driven analytics to inform the design of personalized therapeutic nanoplatforms.

4. Clinical Trial Progress

Between 2019 and 2024, the clinical trial landscape of cancer nanomedicine has expanded steadily, reflecting both the promise and challenges of translating nanoscale innovations into real-world therapies. Dozens of trials across North America, Europe, and Asia have evaluated lipid-based nanoparticles, polymeric systems, inorganic carriers, and hybrid nanosystems in a wide range of malignancies. Collectively, these studies highlight the dual focus of the field: improving therapeutic efficacy while minimizing toxicity [23]. Liver cancer has remained a key focus, with lipid nanoparticle formulations of chemotherapeutics and siRNA therapies showing encouraging results in hepatocellular carcinoma. Several trials reported improved drug accumulation in tumor tissue compared to conventional regimens, translating into prolonged progression-free survival with lower systemic toxicity.Lung cancer, particularly non-small cell lung cancer (NSCLC), has also been an active area. Polymeric micelle and dendrimer-based systems co-delivering chemotherapeutics and nucleic acids have demonstrated the ability to overcome resistance mechanisms, though patient outcomes remain modest in heavily pretreated populations [24].

Pancreatic cancer, one of the most lethal malignancies, has seen incremental progress with albumin-bound and liposomal formulations of drugs like paclitaxel and irinotecan. While survival benefits have been moderate, these platforms consistently reduce adverse events and improve quality of life, making them valuable adjuncts in multimodal regimens. Breast cancer continues to lead in nanomedicine approvals and clinical exploration. Trials with liposomal doxorubicin, albumin-bound paclitaxel, and antibody-nanoparticle conjugates have confirmed superior tolerability profiles, with reduced cardiotoxicity and neuropathy compared to conventional chemotherapy. Importantly, patient-reported outcomes point to improved adherence and fewer treatment interruptions. Brain tumors, particularly glioblastoma, remain a formidable challenge due to the blood–brain barrier [25]. Innovative platforms such as transferrin-conjugated liposomes and exosome-based nanocarriers are under investigation, with early-phase trials suggesting enhanced delivery across the barrier. While efficacy data are still preliminary, these strategies represent a breakthrough pathway for one of oncology's most treatment-resistant cancers.Despite these advances, several barriers impede broader success. The complexity of trial design, including the need for molecularly stratified patient cohorts, has slowed recruitment and extended timelines. Regulatory hurdles persist, as agencies demand rigorous long-term safety data for materials with uncertain biodistribution or clearance [26]. Moreover, the high cost of nanoparticle manufacturing and scale-up continues to restrict accessibility and commercial viability, particularly in low- and middle-income countries.Overall, the 2019–2024 period demonstrates that cancer nanomedicine is transitioning from proof-of-concept to clinically relevant interventions. While breakthroughs have been incremental rather than revolutionary, the consistent improvements in tolerability, patient quality of life, and, in some cases, survival outcomes, affirm nanomedicine's role as a cornerstone in the evolving landscape of precision oncology [27].

5. Translational Challenges

Despite the rapid growth of nanotechnology in oncology, the path from bench to bedside is far from straightforward. Multiple scientific, technical, and regulatory hurdles continue to limit the seamless translation of experimental nanoplatforms into routine clinical practice. Understanding these challenges is crucial to refining future strategies and ensuring sustainable progress.Tumor heterogeneity and delivery barriers represent one of the most persistent obstacles. Tumors vary not only between patients but also within different regions of the same lesion, with fluctuating vasculature, stromal density, and immune cell infiltration [28]. These factors undermine the enhanced permeability and retention (EPR) effect that many nanocarriers rely on, resulting in inconsistent drug accumulation. Moreover, dense extracellular matrices and abnormal interstitial fluid pressures further restrict deep penetration of nanoparticles, reducing therapeutic efficacy.The blood–brain barrier (BBB) poses a particularly formidable challenge for brain tumors and metastases [29]. While nanosystems conjugated with transferrin, peptides, or exosomes have shown promise in crossing the BBB, efficiency remains suboptimal and heterogeneous across patients. Achieving reliable, noninvasive delivery into the central nervous system without disrupting normal brain function continues to be a critical bottleneck for nanomedicine.Manufacturing, scalability, and cost considerations also complicate translation. Many experimental nanocarriers are synthesized through complex, multi-step protocols that are difficult to scale up under Good Manufacturing Practice (GMP) standards. Batch-to-batch variability, stability issues during storage, and high production costs limit the feasibility of commercial deployment. As a result, even clinically successful platforms like liposomes and albumin-bound nanoparticles remain expensive and less accessible in resource-limited settings [30].

Finally, ethical and regulatory aspects of nanomedicine approval add another layer of complexity. Regulatory agencies demand extensive safety and biodistribution data for materials that may persist in the body long-term, delaying approval timelines. Ethical considerations also emerge around patient consent, particularly when trials involve first-in-human nanoplatforms with uncertain risks. Furthermore, the lack of standardized frameworks for evaluating nanomedicine safety and efficacy leads to inconsistencies across global regulatory systems, complicating international clinical development.In sum, while nanomedicine holds undeniable promise, its clinical future depends on systematically addressing these translational barriers [31]. Advances in tumor biology modeling, BBB-penetrant nanocarriers, scalable manufacturing technologies, and harmonized regulatory guidelines will be essential to unlock the full potential of nanoscale therapies in oncology [32].

6. Future Perspectives

As oncology enters a new decade, cancer nanomedicine is poised to evolve from incremental improvements to transformative innovations. The next generation of nanosystems will likely be AI-integrated, stimuli-responsive, and bioinspired platforms designed for maximal precision and minimal toxicity. Smart nanoparticles capable of responding to tumor-specific triggers such as pH, hypoxia, or enzymatic activity will enable on-demand drug release, while bioinspired carriers (e.g., exosomes, cell membrane–coated nanoparticles) will offer unmatched immune

evasion and targeting capabilities [33]. Layering artificial intelligence into the design process will accelerate the optimization of these systems, ensuring highly customized therapeutic strategies.The integration of omics with machine learning will further drive precision oncology. By fusing genomics, transcriptomics, proteomics, and metabolomics data into predictive models, researchers can forecast treatment responses and design nanocarriers tailored to an individual patient's tumor profile. In this vision, every patient receives not a generic nanoparticle but a bespoke therapeutic system engineered based on their molecular signature a true realization of personalized nanomedicine.On the clinical side, innovative trial designs will be critical to translating these technologies efficiently [34]. Traditional randomized controlled trials often fail to capture the complexity of personalized nanotherapies. Instead, adaptive, basket, and umbrella trial frameworks will allow the testing of multiple targets, biomarkers, or drug-nanoparticle combinations within flexible structures. These approaches not only streamline recruitment but also generate data more reflective of real-world tumor diversity [35].A roadmap for clinical translation and commercialization must also address existing bottlenecks. Scalable, GMP-compliant manufacturing pipelines, global regulatory harmonization, and strategies to reduce production costs will be essential to ensure equitable access. Partnerships between academia, industry, and policy-makers will determine whether cutting-edge nanotherapies remain niche innovations or become mainstream oncology tools accessible to patient's worldwide.Ultimately, the vision for 2025 and beyond is one of convergence: nanotechnology, systems biology, artificial intelligence, and clinical innovation uniting to redefine how cancer is diagnosed and treated. With sustained investment and interdisciplinary collaboration, nanomedicine can transition from promise to practice, offering not just longer survival but also improved quality of life for patients facing the world's most formidable malignancies [36]. (Figure 3)



Figure 3. Vision for cancer nanomedicine in the next decade: integrating AI-driven design, omics-based personalization, adaptive trial structures, and scalable translation pathways into a unified framework.

7. Conclusion

Cancer nanomedicine has matured from a theoretical concept into a clinically relevant discipline, steadily reshaping the therapeutic landscape over the past decade. By harnessing the unique properties of lipid-based carriers, polymeric nanostructures, inorganic systems, and bioinspired platforms, researchers have begun to overcome the long-standing barriers of conventional oncology systemic toxicity, therapeutic resistance, and lack of precision. The integration of omics technologies with nanocarrier design, further empowered by artificial intelligence, offers a powerful blueprint for developing highly personalized therapies that align with the molecular complexities of individual tumors.Clinical trials conducted between 2019 and 2024 demonstrate incremental but meaningful progress: improvements in tolerability, patient quality of life, and in some cases survival outcomes across liver, lung, pancreatic, breast, and brain cancers. Yet, translation remains hindered by biological hurdles such as tumor heterogeneity and the blood–brain barrier, as well as by manufacturing, scalability, cost, and regulatory uncertainties. Addressing these bottlenecks will be essential to move beyond niche applications and ensure equitable global access to advanced nanomedicines.Looking forward, the convergence of stimuli-responsive nanoplatforms, bioinspired carriers, and AI-driven multi-omics integration sets the stage for the next generation of precision oncology. Innovative trial designs and streamlined regulatory frameworks will accelerate the journey from laboratory innovation to bedside adoption. Ultimately, cancer nanomedicine is not just about delivering drugs more efficiently it represents a paradigm shift toward therapies that are smarter, safer, and more attuned to the biological and personal realities of patients. With sustained interdisciplinary collaboration, the next decade holds the promise of transforming nanomedicine from incremental innovation into a cornerstone of mainstream cancer care.

References

1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians, 71*(3), 209–249. https://doi.org/10.3322/caac.21660
2. Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., Engelman, J. A., & Dranoff, G. (2017). Prospects for combining targeted and conventional cancer therapy with immunotherapy. *Nature Reviews Cancer, 17*(5), 286–301. https://doi.org/10.1038/nrc.2017.17

2. Ganesh, K., & Massagué, J. (2021). Targeting metastatic cancer. *Nature Medicine, 27*(1), 34–44. https://doi.org/10.1038/s41591-020-01195-4

3. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. *Nature Reviews Cancer, 17*(1), 20–37. https://doi.org/10.1038/nrc.2016.108
4. Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. *Cancer Research, 46*(12 Part 1), 6387–6392.
5. Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. *Journal of Controlled Release, 160*(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
6. He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019). Survey of clinical translation of cancer nanomedicines—Lessons learned from successes and failures. *Accounts of Chemical Research, 52*(9), 2445–2461. https://doi.org/10.1021/acs.accounts.9b00220
7. Liz-Marzán, L. M., Nel, A. E., Brinker, C. J., Chan, W. C. W., Chen, C., Chen, X., Ho, D., Hu, T., Kataoka, K., Kotov, N. A., Parak, W. J., & Stevens, M. M. (2022). Nanomaterials for cancer therapy: Progress and perspectives. *ACS Nano, 16*(9), 13257–13295. https://doi.org/10.1021/acsnano.2c05954
8. Shi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020). The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. *Theranostics, 10*(17), 7921–7924. https://doi.org/10.7150/thno.49577
9. Zhang, Y., Li, M., Gao, X., Chen, Y., & Liu, T. (2019). Nanotechnology in cancer diagnosis: Progress and challenges. *Journal of Hematology & Oncology, 12*(1), 137. https://doi.org/10.1186/s13045-019-0833-6
10. Clack, K., Soda, N., Kasetsirikul, S., Mahmudunnabi, R. G., Nguyen, N. T., & Shiddiky, M. J. A. (2023). Cancer nanomedicine and exosomes: Emerging platforms for diagnosis and therapy. *Small, 19*(16), 2205856. https://doi.org/10.1002/smll.202205856
11. Woodman, C., Vundu, G., George, A., & Wilson, C. M. (2021). Applications and strategies in nanodiagnosis and nanotherapy in cancer. *Seminars in Cancer Biology, 69*, 349–364. https://doi.org/10.1016/j.semcancer.2019.09.001
12. 10. Stylianou, A., Mpekris, F., Voutouri, C., Papoui, A., Constantinidou, A., Kitiris, E., Kailides, M., & Stylianopoulos, T. (2022). Design and development of nanomedicines for cancer therapy: A tumor microenvironment perspective. *Acta Biomaterialia, 154*, 324–340. https://doi.org/10.1016/j.actbio.2022.09.020
13. 11. Wei, G., Wang, Y., Yang, G., Wang, Y., & Ju, R. (2021). Advances in nanomedicine for cancer therapy. *Theranostics, 11*(14), 6370–6392. https://doi.org/10.7150/thno.62427
14. 11. Ghezzi, M., Pescina, S., Padula, C., Santi, P., Del Favero, E., Cantu, L., & Nicoli, S. (2021). Polymeric nanocarriers in cancer therapy. *Journal of Controlled Release, 332*, 312–328. https://doi.org/10.1016/j.jconrel.2021.02.010
15. 11. Fang, F., Wang, S., Song, Y., Sun, M., Chen, W., Zhao, D., Zhang, J., et al. (2023). Innovative nanomedicines in oncology. *Nature Communications, 14*, 1660. https://doi.org/10.1038/s41467-023-37356-2

16. 12. van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019). Smart cancer nanomedicine. *Nature Nanotechnology, 14*(11), 1007–1017. https://doi.org/10.1038/s41565-019-0567-y
17. 12. de Lázaro, I., & Mooney, D. J. (2021). Tissue engineering and cancer therapy: New tools and insights. *Nature Materials, 20*(11), 1469–1479. https://doi.org/10.1038/s41563-021-01048-3
18. 13. Sun, D., Zhou, S., & Gao, W. (2020). What went wrong with anticancer nanomedicine design and how to make it right. *ACS Nano, 14*(10), 12281–12290. https://doi.org/10.1021/acsnano.0c07600
19. 13. Caracciolo, G., Vali, H., Moore, A., & Mahmoudi, M. (2019). Challenges in cancer nanomedicine. *Nano Today, 27*, 6–10. https://doi.org/10.1016/j.nantod.2019.05.009

13. Zhang, P., Xiao, Y., Sun, X., Lin, X., Koo, S., Yaremenko, A. V., Qin, D., Kong, N., Farokhzad, O. C., & Tao, W. (2023). Emerging frontiers of nanomedicine for cancer immunotherapy. *Med, 4*(2), 147–173. https://doi.org/10.1016/j.medj.2022.12.004

20. Hosseini, S., Vázquez-Villegas, P., Rito-Palomares, M., & Martinez-Chapa, S. O. (Eds.). (2018). *Enzyme-linked immunosorbent assay (ELISA): From A to Z.* Springer. https://doi.org/10.1007/978-981-10-8544-1

14. Letovanec, I., Finn, S., Zygoura, P., Smyth, P., Soltermann, A., Bubendorf, L., Speel, E. J., Marchetti, A., Nonaka, D., Monkhorst, K., … O'Brien, C. (2018). Testing for biomarkers in lung cancer: Perspectives from clinical practice. *Journal of Thoracic Oncology, 13*(3), 413–424. https://doi.org/10.1016/j.jtho.2017.12.001

15. Cason, C., D'Accolti, M., Soffritti, I., Mazzacane, S., Comar, M., & Caselli, E. (2022). The role of microbiota in cancer: Insights from microbial studies. *Frontiers in Microbiology, 13*, 969863. https://doi.org/10.3389/fmicb.2022.969863

21. Zhu, H., Zhang, H., Xu, Y., Laššáková, S., Korabečná, M., & Neužil, P. (2020). PCR-based technologies for point-of-care diagnostics. *BioTechniques, 69*(5), 317–325. https://doi.org/10.2144/btn-2020-0050
22. Satpathy, S., Jaehnig, E. J., Krug, K., Kim, B. J., Saltzman, A. B., Chan, D. W., Holloway, K. R., Anurag, M., Huang, C., Singh, P., et al. (2020). Microscaled proteogenomic methods for precision oncology. *Nature Communications, 11*(1), 532. https://doi.org/10.1038/s41467-019-14125-0
23. 18. Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020). The emerging role of epigenetic therapeutics in immuno-oncology. *Nature Reviews Clinical Oncology, 17*(2), 75–90. https://doi.org/10.1038/s41571-019-0266-4
24. 18. Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021). Metabolic control of epigenetics and its role in cancer. *CA: A Cancer Journal for Clinicians, 71*(4), 333–358. https://doi.org/10.3322/caac.21695
25. 18. Rodon, J., Soria, J. C., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019). Genomics and the continuum of

cancer care. *Nature Medicine, 25*(5), 751–754. https://doi.org/10.1038/s41591-019-0416-7

26. 18. Nusinow, D. P., Szpyt, J., Ghandi, M., Rose, C. M., McDonald, E. R., Kalocsay, M., Jané-Valbuena, J., Gelfand, E., Schweppe, D. K., Jedrychowski, M., et al. (2020). Quantitative proteomics of the cancer cell line encyclopedia. *Cell, 180*(2), 387–402.e16. https://doi.org/10.1016/j.cell.2019.12.023
27. 18. Gohil, S. H., Iorgulescu, J. B., Braun, D. A., Keskin, D. B., & Livak, K. J. (2021). Applications of single-cell sequencing in cancer. *Nature Reviews Clinical Oncology, 18*(4), 244–256. https://doi.org/10.1038/s41571-020-00443-2
28. 18. Berger, M. F., & Mardis, E. R. (2018). The emerging landscape of precision oncology. *Nature Reviews Clinical Oncology, 15*(6), 353–364. https://doi.org/10.1038/s41571-018-0006-2
29. 19. Stubbington, M. J. T., Rozenblatt-Rosen, O., Regev, A., & Teichmann, S. A. (2017). Single-cell transcriptomics to explore the immune system in health and disease. *Science, 358*(6359), 58–63. https://doi.org/10.1126/science.aan6828
30. 19. Suhre, K., McCarthy, M. I., & Schwenk, J. M. (2021). Genetics meets proteomics: Perspectives for large-scale and population-based studies. *Nature Reviews Genetics, 22*(1), 19–37. https://doi.org/10.1038/s41576-020-00297-2
31. Zhang, Z., Xu, X., Zhang, D., Zhao, S., Wang, C., Zhang, G., Chen, W., Liu, J., Gong, H., Rixiati, Y., Li, S., Shen, T., & Li, J. (2024). *Cell Metabolism, 36*(4), 541. https://doi.org/10.1016/j.cmet.2024.541
32. Hong, F., Lin, C. Y., Yan, J., Dong, Y., Ouyang, Y., Kim, D., Zhang, X., Liu, B., Sun, S., Gu, W., & Li, Z. (2022). *Hepatology, 76*(6), 1587. https://doi.org/10.1002/hep.1587
33. Wu, S., Wang, J., Fu, Z., Familiari, G., Relucenti, M., Aschner, M., Li, X., Chen, H., & Chen, R. (2023). *Nano Letters, 23*(5), 1970. https://doi.org/10.1021/nl23-1970
34. Wang, L., Huang, X., You, X., Yi, T., Lu, B., Liu, J., Lu, G., Ma, M., Zou, C., Wu, J., & Zhao, W. (2020). *Signal Transduction and Targeted Therapy, 5*(1), 196. https://doi.org/10.1038/s41392-020-0196
35. Bock, C., Datlinger, P., Chardon, F., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., Stanley, G., Chen, S., Garnett, M., Li, W., Moffat, J., Qi, L. S., Shapiro, R. S., Shendure, J., Weissman, J. S., … Zhuang, X. (2022). *Nature Reviews Methods Primers, 2*, 8. https://doi.org/10.1038/s43586-022-00008
36. Pan, Y., Chen, H., Zhang, X., Liu, W., Ding, Y., Huang, D., Zhai, J., Wei, W., Wen, J., Chen, D., Zhou, Y., Liang, C., Wong, N., Man, K., Cheung, A. H., Wong, C. C., & Yu, J. (2023). *Cell Reports Medicine, 4*(5), 101144. https://doi.org/10.1016/j.xcrm.2023.101144